Covered recipient · General Payments record
BARRY J KUTTNER
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$138.69
6 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $138.69 | 6 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | $44.60 | 2 |
| Janssen Biotech, Inc. | $27.24 | 1 |
| E.R. Squibb & Sons, L.L.C. | $25.39 | 1 |
| PFIZER INC. | $21.61 | 1 |
| Kerecis Limited | $19.85 | 1 |
Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BARRY J KUTTNER
NPI 1487614293 · CMS profile ID 111852
Allopathic & Osteopathic Physicians / Dermatology
DELRAY BEACH, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1487614293?year=2023&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BARRY J KUTTNER, NPI 1487614293, CMS profile ID 111852. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487614293?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). BARRY J KUTTNER, NPI 1487614293, CMS profile ID 111852. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487614293?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- BARRY J KUTTNER, NPI 1487614293, CMS profile ID 111852, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1487614293?year=2023&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
6 matching records · $138.69 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–6 of 6.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Inc. | $18.96 | 09/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053800353 | CMS |
| Kerecis Limited | $19.85 | 05/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056308265 | CMS |
| PFIZER INC. | $21.61 | 03/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050555253 | CMS |
| Janssen Biotech, Inc. | $27.24 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988183723 | CMS |
| E.R. Squibb & Sons, L.L.C. | $25.39 | 02/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015512701 | CMS |
| Sun Pharmaceutical Industries Inc. | $25.64 | 01/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053800359 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2024 | Principal investigator | $700.00 | 1 |
| PY2023 | Principal investigator | $16,868.27 | 29 |
| PY2022 | Principal investigator | $44,738.46 | 42 |
| PY2021 | Recipient | $11,453.00 | 4 |
| PY2021 | Principal investigator | $67,841.53 | 50 |
| PY2020 | Principal investigator | $261,290.81 | 68 |
| PY2019 | Recipient | $27,860.00 | 6 |
| PY2019 | Principal investigator | $204,941.02 | 55 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
68 records in PY2020
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AbbVie Inc. | $160.00 | 12/30/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | M16-045 | No dispute reported | 06/30/2026 | 721202571 |
| Principal investigator 1 | AbbVie Inc. | $2,502.50 | 12/30/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | M16-045 | No dispute reported | 06/30/2026 | 721202573 |
| Principal investigator 1 | PFIZER INC. | $9,969.13 | 12/17/2020 | Non-covered Recipient Entity Integrated Clinical Research LLC | A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 742898111 |
| Principal investigator 1 | Bausch Health US, LLC | $250.00 | 12/14/2020 | Non-covered Recipient Individual | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 737375509 |
| Principal investigator 1 | LEO Pharma AS | $3,614.00 | 11/24/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | LONG-TERM EXTENSION TRIAL IN SUBJECTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS TRALOKINUMAB TRIALS - ECZTEND | No dispute reported | 06/30/2026 | 746673713 |
| Principal investigator 1 | Bausch Health US, LLC | $250.00 | 11/13/2020 | Non-covered Recipient Individual | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 737375345 |
| Principal investigator 1 | Bausch Health US, LLC | $5,670.00 | 11/13/2020 | Non-covered Recipient Individual | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 737375359 |
| Principal investigator 1 | PFIZER INC. | $625.75 | 10/30/2020 | Non-covered Recipient Entity Integrated Clinical Research LLC | A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 742910949 |
| Principal investigator 1 | PFIZER INC. | $1,134.00 | 10/17/2020 | Non-covered Recipient Entity Integrated Clinical Research LLC | A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 742907969 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,392.25 | 10/09/2020 | Non-covered Recipient Entity Integrated Clincal Rsrch Llc | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719503143 |
| Principal investigator 1 | Bausch Health US, LLC | $250.00 | 10/05/2020 | Non-covered Recipient Individual | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 737375229 |
| Principal investigator 1 | Bausch Health US, LLC | $4,477.50 | 10/05/2020 | Non-covered Recipient Individual | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 737375247 |
| Principal investigator 1 | AbbVie Inc. | $3,846.25 | 09/30/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | M16-045 | No dispute reported | 06/30/2026 | 721187997 |
| Principal investigator 1 | AbbVie Inc. | $640.00 | 09/23/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | M16-766 | No dispute reported | 06/30/2026 | 721186445 |
| Principal investigator 1 | Bausch Health US, LLC | $250.00 | 09/14/2020 | Non-covered Recipient Individual | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 737375157 |
| Principal investigator 1 | Bausch Health US, LLC | $14,364.00 | 09/08/2020 | Non-covered Recipient Individual | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 737375151 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $300.00 | 08/24/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 724473929 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,190.50 | 08/21/2020 | Non-covered Recipient Entity Integrated Clincal Rsrch Llc | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719503139 |
| Principal investigator 1 | AbbVie Inc. | $2,601.25 | 07/30/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | M16-045 | No dispute reported | 06/30/2026 | 721177535 |
| Principal investigator 1 | Bausch Health US, LLC | $765.00 | 07/24/2020 | Non-covered Recipient Individual | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 737374859 |
| Principal investigator 1 | Janssen Research & Development, LLC | $33.10 | 07/17/2020 | Non-covered Recipient Entity Integrated Clincal Rsrch Llc | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719503127 |
| Principal investigator 1 | Janssen Research & Development, LLC | $75.00 | 07/17/2020 | Non-covered Recipient Entity Integrated Clincal Rsrch Llc | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719503131 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,646.75 | 07/17/2020 | Non-covered Recipient Entity Integrated Clincal Rsrch Llc | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719503135 |
| Principal investigator 1 | PFIZER INC. | $6,500.00 | 07/17/2020 | Non-covered Recipient Entity Integrated Clinical Research LLC | AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 742906927 |
| Principal investigator 1 | AbbVie Inc. | $297.50 | 07/16/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | M16-045 | No dispute reported | 06/30/2026 | 721176047 |
| Principal investigator 1 | Bausch Health US, LLC | $250.00 | 07/13/2020 | Non-covered Recipient Individual | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 737374803 |
| Principal investigator 1 | AbbVie Inc. | $293.75 | 07/06/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | M16-045 | No dispute reported | 06/30/2026 | 721174747 |
| Principal investigator 1 | Bausch Health US, LLC | $2,947.50 | 07/03/2020 | Non-covered Recipient Individual | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 737374767 |
| Principal investigator 1 | Bausch Health US, LLC | $700.00 | 07/03/2020 | Non-covered Recipient Individual | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 737374775 |
| Principal investigator 1 | Janssen Research & Development, LLC | $575.00 | 06/19/2020 | Non-covered Recipient Entity Integrated Clincal Rsrch Llc | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719503111 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 06/19/2020 | Non-covered Recipient Entity Integrated Clincal Rsrch Llc | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719503115 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,715.00 | 06/19/2020 | Non-covered Recipient Entity Integrated Clincal Rsrch Llc | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719503119 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,329.50 | 06/19/2020 | Non-covered Recipient Entity Integrated Clincal Rsrch Llc | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719503123 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,105.75 | 06/06/2020 | Non-covered Recipient Entity Integrated Clincal Rsrch Llc | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719503097 |
| Principal investigator 1 | Janssen Research & Development, LLC | $75.00 | 06/06/2020 | Non-covered Recipient Entity Integrated Clincal Rsrch Llc | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719503101 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18.88 | 06/06/2020 | Non-covered Recipient Entity Integrated Clincal Rsrch Llc | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719503105 |
| Principal investigator 1 | AbbVie Inc. | $6,139.75 | 06/01/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | M16-045 | No dispute reported | 06/30/2026 | 721169237 |
| Principal investigator 1 | AbbVie Inc. | $120.00 | 05/26/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | M16-045 | No dispute reported | 06/30/2026 | 721166965 |
| Principal investigator 1 | AbbVie Inc. | $3,500.00 | 05/19/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | M16-046 | No dispute reported | 06/30/2026 | 721166253 |
| Principal investigator 1 | VYNE Pharmaceuticals Inc. | $900.00 | 05/19/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | MTI-117 | No dispute reported | 06/30/2026 | 753087489 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14.86 | 05/06/2020 | Non-covered Recipient Entity Integrated Clincal Rsrch Llc | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719503081 |
| Principal investigator 1 | Janssen Research & Development, LLC | $67,458.25 | 05/06/2020 | Non-covered Recipient Entity Integrated Clincal Rsrch Llc | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719503089 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16.01 | 05/06/2020 | Non-covered Recipient Entity Integrated Clincal Rsrch Llc | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719503093 |
| Principal investigator 1 | AbbVie Inc. | $500.00 | 05/05/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | M16-045 | No dispute reported | 06/30/2026 | 721165075 |
| Principal investigator 1 | AbbVie Inc. | $2,026.25 | 04/30/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | M16-045 | No dispute reported | 06/30/2026 | 721163171 |
| Principal investigator 1 | Bausch Health US, LLC | $5,450.00 | 04/30/2020 | Non-covered Recipient Individual | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 737374053 |
| Principal investigator 1 | Bausch Health US, LLC | $5,450.00 | 04/27/2020 | Non-covered Recipient Individual | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 737373985 |
| Principal investigator 1 | PFIZER INC. | $6,500.00 | 04/21/2020 | Non-covered Recipient Entity Integrated Clinical Research LLC | A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 742909683 |
| Principal investigator 1 | Janssen Research & Development, LLC | $75.00 | 04/17/2020 | Non-covered Recipient Entity Integrated Clincal Rsrch Llc | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719503085 |
| Principal investigator 1 | AbbVie Inc. | $3,503.75 | 04/16/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | M16-045 | No dispute reported | 06/30/2026 | 721160841 |
| Principal investigator 1 | Bausch Health US, LLC | $5,450.00 | 04/06/2020 | Non-covered Recipient Individual | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 737373909 |
| Principal investigator 1 | AbbVie Inc. | $1,073.75 | 04/01/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | M16-045 | No dispute reported | 06/30/2026 | 721159511 |
| Principal investigator 1 | AbbVie Inc. | $1,201.25 | 03/30/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | M16-045 | No dispute reported | 06/30/2026 | 721157797 |
| Principal investigator 1 | AbbVie Inc. | $1,753.75 | 03/24/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | M16-766 | No dispute reported | 06/30/2026 | 721156625 |
| Principal investigator 1 | VYNE Pharmaceuticals Inc. | $6,050.00 | 03/20/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | MTI-117 | No dispute reported | 06/30/2026 | 753087493 |
| Principal investigator 1 | AbbVie Inc. | $112.50 | 03/19/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | M16-766 | No dispute reported | 06/30/2026 | 721156085 |
| Principal investigator 1 | LEO Pharma AS | $325.00 | 03/18/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | LONG-TERM EXTENSION TRIAL IN SUBJECTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS TRALOKINUMAB TRIALS - ECZTEND | No dispute reported | 06/30/2026 | 746667985 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,550.00 | 03/05/2020 | Non-covered Recipient Entity Integrated Clincal Rsrch Llc | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719503065 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,597.30 | 03/05/2020 | Non-covered Recipient Entity Integrated Clincal Rsrch Llc | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719503069 |
| Principal investigator 1 | Janssen Research & Development, LLC | $177.00 | 03/05/2020 | Non-covered Recipient Entity Integrated Clincal Rsrch Llc | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719503073 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17.53 | 03/05/2020 | Non-covered Recipient Entity Integrated Clincal Rsrch Llc | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 719503077 |
| Principal investigator 1 | LEO Pharma AS | $2,405.00 | 03/03/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | LONG-TERM EXTENSION TRIAL IN SUBJECTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS TRALOKINUMAB TRIALS - ECZTEND | No dispute reported | 06/30/2026 | 746667359 |
| Principal investigator 1 | AbbVie Inc. | $1,398.75 | 02/28/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | M16-045 | No dispute reported | 06/30/2026 | 721152817 |
| Principal investigator 1 | AbbVie Inc. | $500.00 | 02/26/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | M16-045 | No dispute reported | 06/30/2026 | 721152163 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $300.00 | 02/24/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 724455867 |
| Principal investigator 1 | LEO Pharma AS | $1,264.00 | 01/28/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | LONG-TERM EXTENSION TRIAL IN SUBJECTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS TRALOKINUMAB TRIALS - ECZTEND | No dispute reported | 06/30/2026 | 746666411 |
| Principal investigator 1 | AbbVie Inc. | $3,603.75 | 01/13/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | M16-045 | No dispute reported | 06/30/2026 | 721145091 |
| Principal investigator 1 | AbbVie Inc. | $792.50 | 01/03/2020 | Non-covered Recipient Entity INTEGRATED CLINICAL RESEARCH LLC | M16-766 | No dispute reported | 06/30/2026 | 721144225 |